Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

341.88 -0.23 (-0.07%)
Streaming Delayed Price Updated: 1:31 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,043,928
Open 344.33
Bid (Size) 341.78 (2)
Ask (Size) 341.98 (1)
Prev. Close 342.10
Today's Range 341.76 - 347.80
52wk Range 231.87 - 384.44
Shares Outstanding N/A
Dividend Yield 0.99%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
FDA Gives Conditional Approval For Eli Lilly's Drug For Rare Blood Cancer
 
Via Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga

Performance

YTD
-6.33%
-6.33%
1 Month
-6.55%
-6.55%
3 Month
-5.58%
-5.58%
6 Month
+5.47%
+5.47%
1 Year
+39.32%
+39.32%

More News

Read More
Is It Too Late to Buy Eli Lilly Stock?
Via The Motley Fool
Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
Via Benzinga
Where’s The Bathroom? Why People with Ulcerative Colitis Need To Plan Ahead
Via Brandpoint
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Via The Motley Fool
Good News, LLY Stock Invetors! Eli Lilly Is Poised for a Promising 2023.
Via InvestorPlace
The 3 Best Biotech Stocks Under $1 to Buy for January
Via InvestorPlace
Could This New Drug Indication Be a Winner for Eli Lilly?
Via The Motley Fool
2 Ultra-Safe Dividend Stocks to Own in 2023
Via The Motley Fool
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
Via The Motley Fool
FDA Rejects Eli Lilly's Donanemab For Alzheimer's Disease, Needs More Data
Via Benzinga
Cassava Sciences Shares Fall As Alzheimer's Candidate Worsens Patients With Moderate Disease
Via Benzinga
3 Drug Stocks With Promising Pipelines for 2023
Via InvestorPlace
Google Layoffs 12K Employees, Netflix's Q4 Earnings And CEO Steps Down, FDA Rejects Eli Lilly's Alzheimer's Candidate: Top Stories Friday, Jan. 20
Via Benzinga
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
Via Investor's Business Daily
Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss
Via Benzinga
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
Via Benzinga
National Advertising Division Finds Novartis Breast Cancer Drug Claim Supported in Physician-Directed Messaging, But Not in Ads to Consumers
Via iCrowdNewswire
AbbVie, Eli Lilly Leave UK's Voluntary Medicines Pricing Agreement Over Increasing Prices
Via Benzinga
Gamechanging Weight Loss Drug Could Send LLY Stock Soaring
Via InvestorPlace
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Via Talk Markets
3 Growth Stocks Poised for Huge Gains in 2023
Via The Motley Fool
How Novo Nordisk Just Expanded Its Diabetes Lead Over Pfizer, Eli Lilly
Via Investor's Business Daily
Top-Performing Hedge Fund In 2022 Has This Strategy To Thank: How Much Did It Make Last Year?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.